Objective
Elastin deficiency due to heterozygous loss of an
ELN allele in Williams syndrome causes obstructive
aortopathy characterized by medial thickening and fibrosis and consequent
aortic stiffening. Previous work in Eln-null mice with a
severe arterial phenotype showed that inhibition of mechanistic target of
rapamycin (mTOR), a key regulator of cell growth, lessened the aortic
obstruction but did not prevent early postnatal death. We investigated
effects of mTOR inhibition in Eln-null mice partially
rescued by human ELN that manifest a less severe arterial
phenotype and survive long-term.
Approach and Results
Thoracic aortas of neonatal and juvenile mice with graded elastin
deficiency exhibited increased signaling through both mTOR complex 1 and
complex 2. Despite lower predicted wall stress, there was increased
phosphorylation of focal adhesion kinase, suggestive of greater integrin
activation, and increased transforming growth factor-β signaling
mediators, associated with increased collagen expression. Pharmacologic
blockade of mTOR by rapalogs did not improve luminal stenosis, but reduced
mechanosignaling (in delayed fashion following mTOR complex 1 inhibition),
medial collagen accumulation, and stiffening of the aorta. Rapalog
administration also retarded somatic growth, however, and precipitated
neonatal deaths. Complementary, less toxic strategies to inhibit mTOR via
altered growth factor and nutrient responses were not effective.
Conclusions
In addition to previously demonstrated therapeutic benefits of
rapalogs decreasing smooth muscle cell proliferation in the absence of
elastin, we find that rapalogs also prevent aortic fibrosis and stiffening
attributable to partial elastin deficiency. Our findings suggest that
mTOR-sensitive perturbation of smooth muscle cell mechanosensing contributes
to elastin aortopathy.